Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis.
Aged
Antibodies, Monoclonal, Murine-Derived
/ adverse effects
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cyclophosphamide
/ adverse effects
Doxorubicin
/ adverse effects
Humans
Lymphoma, Large B-Cell, Diffuse
/ drug therapy
Prednisone
Rituximab
/ therapeutic use
Treatment Outcome
Vincristine
/ adverse effects
DLBCL
Diffuse large B-cell lymphoma
Doxorubicin
Hearth failure
Liposomal doxorubicin
Lymphoma
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
14
12
2020
revised:
21
05
2021
accepted:
29
05
2021
pubmed:
5
6
2021
medline:
14
7
2021
entrez:
4
6
2021
Statut:
ppublish
Résumé
Doxorubicin represents the mainstay in the upfront treatment of diffuse large B-cell lymphoma (DLBCL) patients. However, its administration is sometimes hampered by the coexistence of former comorbidities/cardiac issues, especially in the elderly population. Liposome encapsulated drug delivery systems have been adopted to reduce the exposure of normal tissues to the drug, both in solid cancers and lymphomas. Despite claims for lower toxicity, the efficacy of non-pegylated liposome doxorubicin (NPLD) in DLBCL, as compared to standard doxorubicin, has never been established. We systematically reviewed relevant literature of NPLD in lymphoma treatment. Adjusting for age/comorbidities, our metanalysis revealed that the use of combinations including NPLD (R-COMP) were non-inferior in terms of response, overall and progression-free survival to the standard of care (R-CHOP) in overlapping series of DLBCL patients. R-COMP may represent a safe and active option for elderly patients with DLBCL, or for those with some extent of cardiac impairment at baseline.
Identifiants
pubmed: 34087342
pii: S1040-8428(21)00165-7
doi: 10.1016/j.critrevonc.2021.103377
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Murine-Derived
0
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Meta-Analysis
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103377Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.